Search details
1.
Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre.
Anticancer Drugs
; 28(6): 654-659, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28252532
2.
Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?
Semin Oncol
; 50(3-5): 90-101, 2023.
Article
in English
| MEDLINE | ID: mdl-37673696
3.
Whole Breast Irradiation Versus Intraoperative Electron Radiation Therapy for Breast Conserving Therapy: A Large Mature Single Institution Matched-Pair Evaluation of True Local Relapse, Progression Free Survival, and Overall Survival.
Int J Radiat Oncol Biol Phys
; 116(4): 757-769, 2023 Jul 15.
Article
in English
| MEDLINE | ID: mdl-36736632
4.
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
NPJ Breast Cancer
; 9(1): 73, 2023 Sep 08.
Article
in English
| MEDLINE | ID: mdl-37684252
5.
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer.
Cells
; 11(19)2022 10 10.
Article
in English
| MEDLINE | ID: mdl-36231138
6.
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.
Int J Gynecol Cancer
; 20(6): 953-7, 2010 Aug.
Article
in English
| MEDLINE | ID: mdl-20683401
7.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
NPJ Breast Cancer
; 10(1): 13, 2024 Feb 05.
Article
in English
| MEDLINE | ID: mdl-38316819
8.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
NPJ Breast Cancer
; 9(1): 89, 2023 Oct 30.
Article
in English
| MEDLINE | ID: mdl-37903774
9.
Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer.
Crit Rev Oncol Hematol
; 59(3): 226-33, 2006 Sep.
Article
in English
| MEDLINE | ID: mdl-16533603
10.
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy.
Virchows Arch
; 464(1): 85-93, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24233241
11.
Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors.
Urology
; 79(3): 644-9, 2012 Mar.
Article
in English
| MEDLINE | ID: mdl-22386418
12.
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.
Virchows Arch
; 461(2): 129-39, 2012 Aug.
Article
in English
| MEDLINE | ID: mdl-22744290
13.
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Expert Rev Anticancer Ther
; 8(3): 393-402, 2008 Mar.
Article
in English
| MEDLINE | ID: mdl-18366287
Results
1 -
13
de 13
1
Next >
>>